Malin Corporation Plc is a company investing in and supporting highly innovative life sciences companies developing exceptional science and technology to deliver transformative outcomes for patients and create significant value for shareholders. Its purpose is to create shareholder value through the application of long-term capital and strategic support to its investee companies to enable them to reach their value potential.

Employees

Sector

Pharmaceuticals

More about the company

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.100EUR

Average target price

15.50EUR

Spread / Average Target

+118.31%

Consensus

Market Closed - OTC Markets Other stock markets 09:41:19 2024-09-18 EDT			5-day change	1st Jan Change
6.400 ^USD	+3.23%		-.--%	-

02-26	EARNINGS AND TRADING: Connecting Excellence hails record January fees	AN
02-26	Malin Corporation says CEO Fiona Dunlevy will leave Malin end of May	RE

Market Cap	30.78M 35.04M 28.62M 26.27M 49.35M 3.37B 50.11M 340M 133M 1.66B 132M 129M 5.74B	P/E 2024 *	-	P/E 2025	-8.37x
Enterprise Value	17.88M 20.36M 16.63M 15.26M 28.67M 1.96B 29.11M 197M 77.14M 964M 76.42M 74.77M 3.33B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	63.83%	Yield 2024 *	-	Yield 2025	-

02-26	EARNINGS AND TRADING: Connecting Excellence hails record January fees	AN
02-26	Malin Corporation says CEO Fiona Dunlevy will leave Malin end of May	RE
02-26	Malin Corporation plc Announces Departure of Fiona Dunlevy as CEO At End of May	CI
02-26	Malin Corporation plc Announces Executive Changes	CI
02-26	Malin CEO to Step Down; Chair to Take Executive Role	MT
02-25	Malin Corporation plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
25-08-27	Malin in valuation fall amid Poseida sale, EUR150 million return	AN
25-03-21	Malin completes oversubscribed EUR150 million tender offer	AN
25-03-21	Malin Concludes EUR150 Million Tender Offer	MT
25-03-21	Tranche Update on Malin Corporation plc's Equity Buyback Plan announced on February 19, 2025.	CI
25-03-19	Malin Corporation plc 's Equity Buyback announced on February 19, 2025 has closed with 14,563,106 shares, representing 77.1% for ?150 million.	CI
25-02-19	Irish Life Sciences Investor Malin Launches Tender Offer	MT
25-02-19	Malin Corporation Says Tender Offer Of Up To EUR 150 Million Launched	RE

03-26	Malin : 2026 AGM Voting (2026 AGM Voting Votes for Malin Website)	PU
03-02	Malin : AGM Notice of 2026 Annual General Meeting (MPLC 2026 AGM Notice of AGM FINAL)	PU
03-02	Malin : AGM Form of Proxy (For Information Only) (197908 131OAC 01 WEB)	PU
11-26	Malin : Mycovia Pharmaceuticals, Inc. Announces Publication of 2-Year VIVJOA® Efficacy Results from an Extension of the VIOLET Phase 3 Studies in Women with Recurrent Vulvovaginal Candidiasis (RVVC) in the Journal of Women’s Health	PU
25-04-11	Malin : 2024 Information Statements	PU

Malin Corporation Plc Stock OTC Markets

Stocks

MLLNF

IE00BVGC3741

Pharmaceuticals

Valuation: Malin Corporation Plc

Latest news : Malin Corporation Plc

Press Releases: Malin Corporation Plc

News in other languages: Malin Corporation Plc

Quotes and Performance

Course Extremes

Managers and Directors: Malin Corporation Plc

Other Pharmaceuticals

Financials

Company Profile

Income Statement and Estimates

Analysts' Consensus

19-08-16	AVIS D'ANALYSTES DU JOUR : Walmart, Nvidia, Amazon, Apple, Uber, Bayer, SAP, Maersk, Roche, Carrefour…
15-03-20	La biotech irlandaise Malin lève 330 mlns avec son IPO
15-03-19	La biotech irlandaise Malin lève 330 mlns avec son IPO

Director	Title	Age	Since
William Daniel CHM	Chairman	73	2019-08-01
Jean-Michel Cossery BRD	Director/Board Member	67	2018-07-15
Chris Pedrick BRD	Director/Board Member	49	2022-04-25

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MALIN CORPORATION PLC	+3.23%	-.--%	-	-	35.04M
ELI LILLY AND COMPANY	+0.86%	+1.43%	+47.17%	+163.68%	1,067B
JOHNSON & JOHNSON	+1.59%	+4.09%	+56.51%	+52.50%	635B
ABBVIE INC.	+0.95%	+1.91%	+36.30%	+82.78%	458B
ROCHE HOLDING AG	+0.87%	+7.90%	+37.34%	+31.36%	347B
NOVARTIS AG	+0.79%	+3.83%	+36.94%	+40.85%	295B
ASTRAZENECA PLC	+1.22%	+3.67%	+18.94%	+19.94%	262B
NOVO NORDISK A/S	+1.43%	-1.14%	-28.13%	-39.07%	216B
AMGEN INC.	+1.22%	+2.66%	+22.66%	+59.87%	203B
GILEAD SCIENCES, INC.	-1.18%	-3.70%	+11.28%	+67.52%	161B
Average	+1.09%	+1.33%	+26.56%	+53.27%	404.83B
Weighted average by Cap.	+0.98%	+1.95%	+36.22%	+79.20%

	2024	2025
Net sales	-	-
Net income	-	-6.9M -7.86M -6.42M -5.89M -11.06M -757M -11.23M -76.2M -29.77M -372M -29.49M -28.86M -1.29B
Net Debt	-62.1M -70.7M -57.75M -52.99M -99.57M -6.81B -101M -686M -268M -3.35B -265M -260M -11.57B	-12.9M -14.69M -12M -11.01M -20.68M -1.41B -21M -142M -55.66M -695M -55.14M -53.95M -2.4B

3 years	5.45	6.4
5 years	4.8	7.69
10 years	0	14.55